EverHint – Momentum Swing — Breakout Standard for Mar 30, 2026 – 6 Signals – Energy Leads (4)

6 signals. Energy leads (4). 1 with insider selling. price range $15-$588. sectors: Energy (4), Basic Materials (1), Healthcare (1). full analyst coverage, 50.0% have news.
EverHint – Momentum Swing — Breakout Standard for Mar 30, 2026 – 6 Signals – Energy Leads (4)
Photo by Milos Lopusina / Unsplash

What This Signal Is (Quick)

Breakout Standard is a momentum swing trading strategy focused on Stocks within 3% of 52-week high - standard breakout momentum setups.

Signal Type: Breakout (momentum continuation)

What Makes This Signal:

  • Stock showing strong momentum near or at highs
  • Increased volume confirms institutional interest
  • Breaking out or consolidating near resistance
  • Stocks within 3% of 52-week high - standard breakout momentum setups

Ideal For: Swing traders looking for breakout opportunities with confirmed momentum

Key Criteria:

  • Strong RSI momentum (configurable thresholds)

  • Volume surge above average

  • Price momentum confirmation

  • Minimum ADV: $25M+ (varies by variant)

  • Earnings buffer: 7 days pre/post earnings

  • Variant-specific filters applied

Holding Period: 1-4 weeks
Risk Level: Medium-High


How We Ranked Today

Ranked by composite momentum score (higher = stronger momentum)


📊 Momentum Swing — Breakout Standard Signals (6 Total)

Ranked by score:

Rank Ticker Company Sector Last ($) Score Vol Thrust @52w Insider Net Days → Earnings Est EPS Mkt Cap ($B)
1 YPF YPF Sociedad Anónima Energy 46.12 1.000 1.54x 0.0% $23313.20 18.1
2 EC Ecopetrol S.A. Energy 14.98 0.800 1.68x 0.0% 35 $4819.16 30.8
3 WLK Westlake Corporation Basic Materials 116.00 0.340 1.52x 0.0% 31 $4.20 14.9
4 CLMT Calumet, Inc. Energy 35.04 0.320 3.15x 0.0% 38 $3.57 3.0
5 UTHR United Therapeutics Co... Healthcare 588.36 0.280 2.90x 0.0% $-4.1M 29 $53.13 25.8
6 SOBO South Bow Corporation Energy 34.26 0.120 3.42x 0.0% $2.33 7.1

Field Notes

Sector concentration: Energy (4), Basic Materials (1), Healthcare (1)

Insider selling: UTHR (United Therapeutics Corporation, $-4.1M)

Data coverage: 16.7% insider, 0.0% congressional, 66.7% earnings, 100.0% analyst, 50.0% news


Peer Analysis

Understanding how these stocks relate to their industry peers:

EC (Ecopetrol S.A.): Leads 10 peers: DVN ($51.52, -1.1%), CTRA ($35.91, -1.1%), VG ($16.89, -3.6%), TS ($57.20, -1.9%), YPF ($46.12, +2.1%) | Peer of: CTRA ($35.91, -1.1%), CVX ($210.76, -0.2%), DVN ($51.52, -1.1%) and 9 more

WLK (Westlake Corporation): Leads 10 peers: ALB ($177.22, -1.2%), NEU ($628.19, +0.1%), EMN ($72.55, +1.9%), MOS ($24.98, -0.0%), ICL ($5.19, -0.2%) | Peer of: AA ($63.21, +8.2%), ALB ($177.22, -1.2%), CC ($21.20, -1.9%) and 9 more

UTHR (United Therapeutics Corporation): Leads 10 peers: INCY ($90.33, +0.0%), GMAB ($25.83, +0.0%), RPRX ($46.37, +0.0%), DGX ($197.16, +0.8%), ZBH ($88.62, +0.1%) | Peer of: BIIB ($187.57, +2.0%), BNTX ($85.25, -0.5%), DGX ($197.16, +0.8%) and 6 more

CLMT (Calumet, Inc.): Leads 10 peers: TALO ($16.32, -1.5%), BTE ($4.35, +0.5%), NEXT ($8.04, -1.1%), WKC ($23.06, -1.3%), GEL ($17.75, -0.2%) | Peer of: BKV ($29.27, -2.2%), BTE ($4.35, +0.5%), GEL ($17.75, -0.2%) and 6 more

YPF (YPF Sociedad Anónima): Leads 10 peers: WES ($41.62, -0.4%), VNOM ($46.71, -2.4%), CTRA ($35.91, -1.1%), EC ($14.98, -0.2%), PAA ($22.47, +0.1%) | Peer of: CTRA ($35.91, -1.1%), CVX ($210.76, -0.2%), EC ($14.98, -0.2%) and 6 more

SOBO (South Bow Corporation): Leads 10 peers: FRO ($33.39, -0.8%), CHRD ($146.24, +0.6%), WFRD ($92.62, -3.4%), NOV ($18.56, -6.6%), CNX ($39.98, -1.5%) | Peer of: AM ($23.12, -0.3%), CHRD ($146.24, +0.6%), CNX ($39.98, -1.5%) and 12 more


Recent Headlines

CLMT (Calumet, Inc.)

  • Why Calumet Stock Is Soaring Today (source)
  • Adams Asset Advisors LLC Has $102.46 Million Stock Position in Calumet, Inc. $CLMT (source)
  • Calumet Announces Board Member Will Not Stand for Re-Election (source)

EC (Ecopetrol S.A.)

  • Decisions Adopted by the Shareholders in Ordinary General Meeting held on March 27, 2026 (source)
  • Statement by Ecopetrol's Board of Directors (source)

UTHR (United Therapeutics Corporation)

  • United Therapeutics Corporation Announces TETON-1 Pivotal Study of Tyvaso® Meets Primary Endpoint for Treatment of Idiopathic Pulmonary Fibrosis, Exceeding Impressive Treatment Effect Seen in TETON-2 (source)
  • United Therapeutics (UTHR) Up 5.7% Since Last Earnings Report: Can It Continue? (source)
  • NorthCrest Asset Manangement LLC Purchases 1,843 Shares of United Therapeutics Corporation $UTHR (source)

Market Context

The broader market shows mixed performance with the S&P 500 and Nasdaq declining modestly, while the Dow edges higher, signaling a cautious risk appetite amid uneven sector participation. Elevated VIX levels around 30, despite a slight decline, point to persistent volatility that can amplify intraday swings, creating fertile ground for momentum swing breakout strategies. These conditions favor setups where price action breaks key levels on building momentum, though traders should watch for quick reversals in a choppy environment.

High volatility enhances the potential for sharp intraday moves, aligning well with standard momentum swing breakouts that thrive on exaggerated price extensions. However, the mild downward tilt in major indices suggests limited upside conviction, potentially capping breakout follow-through unless volume confirms. Risk management remains crucial, as fading volatility could lead to false breaks.

Sector rotation appears tilted toward energy as the top-performing area, consistent with Dow strength and broader market caution. This implies defensive momentum plays may outperform, supporting breakout signals in resilient sectors while growth-sensitive areas lag. With only six total signals, selectivity is key to capitalize on volatility-driven opportunities without overexposing to rotational shifts.


Sharing Call-to-Action

🌟 Help the channel grow: like, share, or subscribe if you find value in what EverHint publishes.


Independent, data-driven signals.
No hype. No promotions. Just experimental market research from EverHint.

This is not financial advice. Do your own due diligence.
See https://www.everhint.com/disclaimer/ and https://www.everhint.com/faqs/